Navigation Links
Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS)

JERUSALEM, & LUND, Sweden--(BUSINESS WIRE)--May 1, 2007 - Teva Pharmaceutical Industries Ltd. and Active Biotech AB today announced that data from a 36-week, randomized, double-blind, placebo-controlled Phase IIb study demonstrated that an oral 0.6 mg dose of laquinimod given daily significantly reduced magnetic resonance imaging (MRI) disease activity by 38 percent in RRMS patients and was well tolerated. In addition, there was a favorable trend towards reducing annual relapse rates, the number of relapse-free patients and time to first relapse compared with placebo. Treatment with a 0.3 mg dose showed no statistical significant difference compared with placebo.

These data were presented at the 59th Annual Meeting of the American Academy of Neurology (AAN) in Boston, MA, April 28 - May 5, 2007.

"Current RRMS options are effective for the treatment of the disease, but an oral therapy such as laquinimod would represent a milestone for patients as it would provide them with a completely unique, non-invasive method of drug delivery," said Giancarlo Comi, M.D., Director of Department of Neurology and Institute of Experimental Neurology, Universita Vita-Salute, San Raffaele, Milan, Italy. "Preliminary studies have already demonstrated the positive effect of laquinimod versus placebo, but these new data confirmed that a higher dose was even more effective and remained well tolerated."

The 36-week study evaluated the effect of oral daily 0.3 and 0.6 mg doses of laquinimod on MRI-monitored disease activity in patients with RRMS. The majority of the patients who participated in the study continued treatment with laquinimod in an ongoing, blinded 9 month extension study. This extension study is followed by an open label study where patients will receive 0.6 mg laquinimod for an additional 24 months.

"The results of this study, which once again demonstrate the efficacy and tolerability of once-dai
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
(Date:8/29/2014)...   Mast Therapeutics, Inc. (NYSE MKT: ... Santosh Vetticaden, Chief Medical Officer and Senior Vice ... reasons, in mid-September.  Edwin L. Parsley , ... which Mast acquired earlier this year, will assume ... Chief Medical Officer.  Dr. Parsley previously was with ...
(Date:8/29/2014)... Research and Markets has announced ... Market & Pipeline Insight 2014" report to their ... prevent and eradicate the prevalence of cancer have achieved ... to low specificity, safety and large number of side ... better solution. It has been discovered that peptides can ...
(Date:8/29/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) ... District of New Jersey has ... Sandoz, Inc. regarding United Therapeutics, Remodulin ® product.  In ... U.S. Patent No. 6,765,117 is both valid and enforceable ... generic product until the expiration of that patent in ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2
... off daily GERD medication at 1 year ... after transoral incisionless fundoplication surgery, REDMOND, Wash., ... natural orifice surgery products and procedures, announces,outstanding results ... patients,in the phase 2 multi-center study of the ...
... Dong-A PharmTech Co., Ltd.,announced today that its ... patient, phase 2 proof of concept clinical study ... phosphodiesterase type 5 inhibitor, for,portal hypertension, an unmet ... investigate the safety and efficacy of udenafil in ...
Cached Medicine Technology:EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study 2EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study 3EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study 4Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil 2Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil 3
(Date:8/29/2014)... Colo. (Sept. 2, 2014) A team of scientists ... reported the breakthrough discovery of a process to expand ... These findings could have implications that extend beyond cancer, ... autoimmune diseases., In an article published Aug. ... Charles C. Gates Center for Regenerative Medicine and Stem ...
(Date:8/29/2014)... 2014 LiveOps, Inc., the global leader ... announced that LiveOps has been selected as a call ... of Strength Telethon for the third year in a ... awareness to support MDA’s mission to help children and ... fatal muscle disease. This year’s program includes performances by ...
(Date:8/29/2014)... Reinberg HealthDay Reporter ... majority of American babies are getting the vaccines they ... officials said Thursday. More than 90 percent of ... and rubella (MMR); polio; hepatitis B and chickenpox (varicella), ... Prevention. "Nationally, vaccination among children 19 to 35 ...
(Date:8/29/2014)... 29, 2014 Floors of hospitals and ... wearing socks. Also, many patients are relegated to lying ... surgery recovery, Alzheimer’s, etc. Two inventors from Perrysburg, Ohio, ... patient safety. , This special pair of socks helps ... keeps patients who are relegated to beds or chairs ...
(Date:8/29/2014)... cigarettes in plain packages doesn,t increase the use of ... small stores, according to new research from Australia. ... it tried to prevent Australia from becoming the first ... tobacco products in 2012. Similar legislation is being considered ... surveyed nearly 2,000 adult smokers in Australia before and ...
Breaking Medicine News(10 mins):Health News:CU scientists' discovery could lead to new cancer treatment 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 3Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 4Health News:Most U.S. Babies Get Their Vaccines: CDC 2Health News:Most U.S. Babies Get Their Vaccines: CDC 3Health News:Study Counters Critics of Plainer Cigarette Packaging 2
... New findings from the St. Jude Children,s Research Hospital ... helped identify the mechanism that makes the childhood eye ... tumor develops so rapidly while other cancers can take ... also led investigators to a new treatment target and ...
... launched a freely available website for published research results ... University Pediatric Cancer Genome Project (PCGP). The PCGP is ... entire genomes of both normal and cancer cells from ... identify genetic mistakes that lead to childhood cancers. ...
... MADISON Placing a stent in a key artery in the ... standard surgical treatment of carotid artery disease, according to a ... Vascular Surgery . A team of researchers led ... at University of Wisconsin School of Medicine and Public Health, ...
... 11 (HealthDay News) -- Keeping an eye on Internet search ... an early warning system about potential surges in seasonal flu ... more effective than waiting for outdated government flu case reports, ... reviewed Google Flu Trends data for Baltimore and matched that ...
... laboratory tests of an imaging agent that shows promise for ... brain signs that now can,t confirm a diagnosis until ... ACS Medicinal Chemistry Letters . Masahiro Ono and ... now exists for AD, which is claiming an increasingly heavy ...
... to condescendingly, excluded from a meeting, or ignored by a ... differently depending on whether your co-worker is a man or ... incivility towards colleagues feel negative emotions especially when the ... work, by Kathi Miner from Texas A&M University and Angela ...
Cached Medicine News:Health News:Gene identified as a new target for treatment of aggressive childhood eye tumor 2Health News:Gene identified as a new target for treatment of aggressive childhood eye tumor 3Health News:St. Jude Children's Research Hospital launches data website for genome project 2Health News:Stenting for stroke prevention becoming safer in high-risk patients 2Health News:Internet Flu Searches May Warn of Outbreaks 2Health News:'I feel your pain ...' 2
... Plus Instrument for applications ... ,The VERSASTEP™ Plus ... working length is a ... utilizing radial dilation. It ...
... system device is comprised of the following ... access port are also packaged in the ... cone with 12 mm Step™ cannula assembly ... 12 mm locking cone with 10/12 mm ...
... The Step™ and Mini Step™ device components are ... Step™ Single Use System is supplied sterile in ... packaged in various configurations and combinations. They are ... Access needle and the Step™ radially Expandable Sleeve. ...
... The Premium One-Step™ single-use system device is ... ,The device components for creating each access ... configurations: , Step™ insufflation and access ... packaged separately. , Step™ radially expandable sleeve, ...
Medicine Products: